Taghdiri Andia
Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.
Egypt Heart J. 2024 Jun 7;76(1):71. doi: 10.1186/s43044-024-00506-1.
Long-term cardiovascular complications are common among pediatric cancer survivors, and anthracycline-induced hypertension has become an essential reason for concern. Compared to non-cancer controls, survivors have a higher prevalence of hypertension, and as they age, their incidence rises, offering significant dangers to cardiovascular health.
Research demonstrates that exposure to anthracyclines is a major factor in the development of hypertension in children who have survived cancer. Research emphasizes the frequency and risk factors of anthracycline-induced hypertension, highlighting the significance of routine measurement and management of blood pressure. Furthermore, cardiovascular toxicities, such as hypertension, after anthracycline-based therapy are a crucial be concerned, especially for young adults and adolescents. Childhood cancer survivors deal with a variety of cardiovascular diseases, such as coronary artery disease and cardiomyopathy, which are made worse by high blood pressure. In order to prevent long-term complications, it is essential to screen for and monitor for anthracycline-induced hypertension. Echocardiography and cardiac biomarkers serve as essential tools for early detection and treatment. In order to lower cardiovascular risks in pediatric cancer survivors, comprehensive management strategies must include lifestyle and medication interventions in addition to survivor-centered care programs.
Proactive screening, monitoring, and management measures are necessary for juvenile cancer survivors due to the substantial issue of anthracycline-induced hypertension in their long-term care. To properly include these strategies into survivor-ship programs, oncologists, cardiologists, and primary care physicians need to collaborate together. The quality of life for pediatric cancer survivors can be enhanced by reducing the cardiovascular risks linked to anthracycline therapy and promoting survivor-centered care and research.
长期心血管并发症在儿童癌症幸存者中很常见，蒽环类药物引起的高血压已成为一个值得关注的重要原因。与非癌症对照组相比，幸存者高血压的患病率更高，并且随着年龄增长，其发病率上升，对心血管健康构成重大危险。
研究表明，接触蒽环类药物是癌症幸存儿童发生高血压的主要因素。研究强调了蒽环类药物引起高血压的频率和风险因素，突出了常规测量和管理血压的重要性。此外，基于蒽环类药物的治疗后出现的心血管毒性，如高血压，是一个至关重要的关注点，尤其是对于年轻成年人和青少年。儿童癌症幸存者会面临各种心血管疾病，如冠状动脉疾病和心肌病，而高血压会使这些疾病恶化。为了预防长期并发症，筛查和监测蒽环类药物引起的高血压至关重要。超声心动图和心脏生物标志物是早期检测和治疗的重要工具。为了降低儿童癌症幸存者的心血管风险，综合管理策略除了以幸存者为中心的护理计划外，还必须包括生活方式和药物干预。
由于蒽环类药物引起的高血压在青少年癌症幸存者的长期护理中是一个重大问题，因此积极的筛查、监测和管理措施是必要的。为了将这些策略适当地纳入幸存者计划，肿瘤学家、心脏病学家和初级保健医生需要共同协作。通过降低与蒽环类药物治疗相关的心血管风险，并促进以幸存者为中心的护理和研究，可以提高儿童癌症幸存者的生活质量。
